keyword
MENU ▼
Read by QxMD icon Read
search

Bimatoprost

keyword
https://www.readbyqxmd.com/read/27906815/structural-and-histologic-eyelid-changes-associated-with-6-months-of-topical-bimatoprost-in-the-rabbit
#1
Tiffany L Kent, Philip L Custer
PURPOSE: To determine the periorbital effects of daily 0.03% bimatoprost in New Zealand white (NZW) rabbits. MATERIALS AND METHODS: NZW rabbits were treated with daily 0.03% bimatoprost, artificial tears, or left untreated. Following 3 and 6 months of treatment, eyelid measurements were obtained for both upper and lower eyelid distraction, as well as canthus-to-canthus measurements. Once complete, subjects were humanely euthanized and eyelid tissue was utilized for histology...
November 30, 2016: Journal of Glaucoma
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#2
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27770310/treating-alopecia-areata-current-practices-versus-new-directions
#3
Aditya K Gupta, Jessie Carviel, William Abramovits
Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases...
October 22, 2016: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#4
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
October 19, 2016: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27703324/preservative-free-bimatoprost-0-03-timolol-0-5-fixed-combination-in-patients-with-glaucoma-in-clinical-practice
#5
Stefan Pfennigsdorf, Peter Eschstruth, Stefan Häsemeyer, Cord Feuerhake, Gerrett Brief, Ioana Grobeiu, Andrew Shirlaw
PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting. PATIENTS AND METHODS: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27672307/preservative-free-bimatoprost-0-03-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-in-clinical-practice
#6
Lutz E Pillunat, Peter Eschstruth, Stefan Häsemeyer, Ulrich Thelen, Christian Foja, Richard Leaback, Stefan Pfennigsdorf
BACKGROUND: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. METHODS: This open-label study observed patients who were switched to PF bimatoprost 0...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27633513/tolerability-and-efficacy-of-bimatoprost-0-01%C3%A2-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-evaluated-in-the-taiwanese-clinical-setting-the-asia-pacific-patterns-from-early-access-of-lumigan-0-01%C3%A2-appeal-taiwan-study
#7
Ying Ying Chen, Tsing-Hong Wang, Catherine Liu, Kwou-Yeung Wu, Shin-Lin Chiu, Susan Simonyi, Da-Wen Lu
BACKGROUND: In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %. Given geographic/racial differences in glaucoma presentation, the APPEAL study assessed the occurrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese clinical setting. METHODS: In this multicenter, open-label, observational study, treatment-naïve and previously treated patients with OHT or OAG received once-daily bimatoprost 0...
2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27552406/do-cyclosporine-a-an-il-1-receptor-antagonist-uridine-triphosphate-rebamipide-and-or-bimatoprost-regulate-human-meibomian-gland-epithelial-cells
#8
Wendy R Kam, Yang Liu, Juan Ding, David A Sullivan
PURPOSE: Researchers have hypothesized that treatment with cyclosporine A (CyA), interleukin-1 receptor antagonists (IL-1RA; e.g., anakinra), P2Y2 receptor agonists (e.g., uridine triphosphate; UTP), and rebamipide may alleviate human meibomian gland dysfunction (MGD) and/or dry eye disease. Investigators have also proposed that prostaglandin analogues (e.g., bimatoprost) may induce MGD. Our goal was to determine whether these compounds directly influence human meibomian gland epithelial cell (HMGEC) function...
August 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27550870/efficacy-of-bimatoprost-in-the-treatment-of-non-facial-vitiligo
#9
Nooshin Bagherani, Bruce R Smoller
No abstract text is available yet for this article.
August 23, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27506567/does-the-intraocular-pressure-lowering-effect-of-prostaglandin-analogues-continue-over-the-long-term
#10
Caner Kara, Emine Malkoç Şen, Kadriye Ufuk Elgin, Kurtuluş Serdar, Pelin Yilmazbaş
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41...
August 9, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27377163/successful-treatment-of-pediatric-alopecia-areata-of-the-scalp-using-topical-bimatoprost
#11
Alvin W Li, Richard J Antaya
Alopecia areata (AA) is a genetic and immune-mediated disease that targets anagen hair follicles. Despite limited evidence supporting the efficacy of corticosteroid treatments, they are often prescribed as first-line therapy because of their favorable safety profile. Prostaglandin analogues are currently being studied as an alternate therapy for scalp AA in adults. Herein we present a case of steroid-resistant multifocal AA that was successfully treated with topical bimatoprost.
September 2016: Pediatric Dermatology
https://www.readbyqxmd.com/read/27367743/ocular-hypotensive-effect-of-fixed-combination-brinzolamide-brimonidine-adjunctive-to-a-prostaglandin-analog-a-randomized-clinical-trial
#12
R D Fechtner, J S Myers, D A Hubatsch, D L Budenz, H B DuBiner
PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults with open-angle glaucoma or ocular hypertension and with mean IOP ≥21 and <32 mm Hg, whereas receiving an open-label PGA (latanoprost, bimatoprost, or travoprost)...
July 1, 2016: Eye
https://www.readbyqxmd.com/read/27272076/bimatoprost-0-03-solution-for-the-treatment-of-nonfacial-vitiligo
#13
Pearl E Grimes
BACKGROUND: Topical prostaglandin E<sub>2</sub> has shown efficacy in patients with localized, stable vitiligo. Bimatoprost is a synthetic prostamide (prostaglandin-ethanolamides) F<sub>2</sub>a analog. Bimatoprost 0.03% ophthalmic solution showed efficacy in the treatment of vitiligo in one small study.<br /> OBJECTIVE: To assess the efficacy and safety of bimatoprost 0.03% alone and in combination with a topical steroid (mometasone) compared with mometasone alone in patients with nonsegmental vitiligo on nonfacial areas in a proof-of-concept study...
June 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27187282/changes-in-corneal-biomechanical-properties-after-long-term-topical-prostaglandin-therapy
#14
Na Wu, Yuhong Chen, Xiaobo Yu, Mengwei Li, Wen Wen, Xinghuai Sun
OBJECTIVE: To compare corneal biomechanical properties, measured by a newly developed tonometer (Corneal Visualization Scheimpflug Technology, Corvis ST), in untreated primary open angle glaucoma (POAG) patients, POAG patients with long-term topical prostaglandin analog (PGA) therapy and in normal controls. Further is to investigate the potential effects of PGA on corneal biomechanics. METHODS: In this case-control study, 35 consecutive medication naïve eyes with POAG, 34 POAG eyes with at least 2 years treatment by PGA and 19 normal eyes were included...
2016: PloS One
https://www.readbyqxmd.com/read/27157843/six-month-intraocular-pressure-reduction-with-a-topical-bimatoprost-ocular-insert-results-of-a-phase-ii-randomized-controlled-study
#15
James D Brandt, Kenneth Sall, Harvey DuBiner, Robert Benza, Yair Alster, Gary Walker, Charles P Semba
PURPOSE: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. DESIGN: Parallel-arm, multicenter, double-masked, randomized, controlled trial. PARTICIPANTS: One hundred thirty adult OAG or OHT patients. METHODS: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0...
August 2016: Ophthalmology
https://www.readbyqxmd.com/read/27128246/a-comprehensive-approach-to-multimodal-facial-aesthetic-treatment-injection-techniques-and-treatment-characteristics-from-the-harmony-study
#16
Vic A Narurkar, Joel L Cohen, Steven Dayan, Michael S Kaminer, Alexander Rivkin, Ava Shamban, Jonathan M Sykes, Craig F Teller, Susan H Weinkle, W Philip Werschler, Adrienne Drinkwater, Michael L Pucci, Conor J Gallagher
BACKGROUND: The HARMONY study is the first clinical trial to assess the impact of a global approach to facial rejuvenation with several minimally invasive modalities, using patient-reported outcome measures. OBJECTIVE: Provide details of this treatment approach and describe investigators' experiences and recommendations based on this study. METHODS: This multicenter, 4-month study evaluated subject satisfaction with and psychological impact of combined treatment with VYC-20L (Juvéderm Voluma XC), HYC-24L (Juvéderm Ultra XC), HYC-24L+ (Juvéderm Ultra Plus XC), onabotulinumtoxinA (Botox), and bimatoprost 0...
May 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27124878/bimatoprost-0-03-for-the-treatment-of-eyebrow-hypotrichosis
#17
Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman, Zoe Diana Draelos, Derek Jones, Mitchel P Goldman, Michael L Pucci, Amanda VanDenburgh, Emily Weng, Scott M Whitcup
BACKGROUND: Eyebrow loss may have substantial negative functional and social consequences. OBJECTIVE: Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis. METHODS: This multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7...
May 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27115319/efficacy-of-bimatoprost-plus-timolol-fixed-combination-in-open-angle-glaucoma-patients-previously-treated-with-dorzolamide-plus-timolol-fixed-combination
#18
Matteo Sacchi, Claudia Specchia, Susan E Williams, Edoardo Villani, Paolo Nucci
PURPOSE: To evaluate the efficacy and safety of bimatoprost plus timolol fixed combination (BTFC) in patients with primary open angle glaucoma (POAG) previously treated with dorzolamide plus timolol fixed combination (DTFC). MATERIALS AND METHODS: Retrospective, medical records review study. Medical records of patients with POAG previously treated with DTFC and then switched to BTFC for poor intraocular pressure (IOP) control or ocular discomfort were included in the analysis...
April 26, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27103783/a-combined-analysis-of-four-observational-studies-evaluating-the-intraocular-pressure-lowering-ability-and-tolerability-of-bimatoprost-0-01-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension
#19
Annemie Stevens, Milko E Iliev, Leo de Jong, Ioana Grobeiu, Anton Hommer
OBJECTIVE: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. METHODS: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10-14 weeks...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27073587/efficacy-and-safety-of-switching-latanoprost-monotherapy-to-bimatoprost-monotherapy-or-combination-of-brinzolamide-and-latanoprost
#20
Mitsuhiro Imasawa, Joji Tanabe, Fumiko Kashiwagi, Kenji Kashiwagi
PURPOSE: To prospectively assess the efficacy and safety of switching to bimatoprost monotherapy or brinzolamide and latanoprost combination therapy in patients who had been receiving latanoprost monotherapy. METHODS: A prospective, open-label study was conducted. Patients with primary open-angle glaucoma or ocular hypertension who had been receiving latanoprost monotherapy for three months or more were enrolled. Bimatoprost was substituted for latanoprost in one eye (BIM group), and brinzolamide was added to the latanoprost in the other eye (BRZ group) simultaneously...
2016: Open Ophthalmology Journal
keyword
keyword
27282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"